Background
Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children.
Objectives
To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact on active TB, death, and reported adverse events.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017.
Selection criteria
We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo.
Data collection and analysis
Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using risk, incidence rate and hazard ratios and assessed the certainty of evidence using GRADE.
Main results
We included three trials, involving 991 participants, below the age of 13 years, from South Africa and Botswana. Children were randomized to isoniazid prophylaxis or placebo, given daily or three times weekly. The median length of follow-up ranged from 5.7 to 34 months; some were on antiretroviral therapy (ART).
In HIV-positive children not on ART, isoniazid prophylaxis may reduce the risk of active TB (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, low certainty evidence), and death (HR 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, low certainty evidence). One trial (182 participants) reported number of children with laboratory adverse events, which was similar between the isoniazid prophylaxis and placebo groups. No clinical adverse events were reported.
In HIV-positive children on ART, we do not know if isoniazid prophylaxis reduces the risk of active TB (risk ratio (RR) 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, very low certainty evidence) or death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, very low certainty evidence). Two trials (714 participants) reported number of clinical adverse events and three trials (795 participants) reported number of laboratory adverse events; for both categories, the number of adverse events were similar between the isoniazid prophylaxis and placebo groups.
Authors' conclusions
Isoniazid prophylaxis given to all children diagnosed with HIV may reduce the risk of active TB and death in HIV-positive children not on ART in studies from Africa. For children on ART, no clear benefit was detected. .
P L A I N L A N G U A G E S U M M A R Y

Isoniazid prophylaxis for preventing active tuberculosis and death in HIV-positive children
What was the aim of this review?
To summarise the effects of isoniazid prophylaxis on TB, death, and adverse effects in HIV-positive children.
Key messages
In areas of high tuberculosis endemicity, isoniazid prophylaxis prevents active TB and death in HIV-positive children who are not on ART.
We conducted a review to assess the effect of TB medication on active TB or death and its safety in HIV-positive children.
What was studied in the review?
TB is a common cause of severe lung disease and death in HIV-positive children. Childhood TB is common in poor countries, especially those with a coexisting burden of HIV/AIDS disease. HIV-positive children have a higher risk of developing TB than HIV-negative children. Isoniazid prevents TB in HIV-positive adults and is currently used in children who are at high risk of developing TB disease after exposure to someone with TB. However, there is limited information on the effect of isoniazid medication in reducing active TB or death if given to HIV-positive children without known TB contact.
We searched for studies up to 17 February 2017, and found three studies published between 2007 and 2014 that addressed the effect of isoniazid medication compared to no medication on active TB and death in 991 HIV-positive children, below the age of 13 years.
Most of the children were on antiretroviral therapy (ART) and the studies were conducted in South Africa and Botswana. The median length of follow-up ranged from 5.7 to 34 months.
What are the main results of the review?
In HIV-positive children not taking ART, isoniazid medication reduced the number of children developing active TB by 69% (low certainty evidence), and death by 54% (low certainty evidence).
One trial was conducted in HIV-positive children taking ART, and this did not detect any benefit or harm of isoniazid (very low certainty evidence).
The number of children with adverse effects were similar in children receiving isoniazid medication as the control group in both children on ART and not on ART.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Isoniazid prophylaxis compared to placebo for HIV-positive children not on antiretroviral therapy (ART) The basis f or the assumed risk is the m edian control group risk across studies. The corresponding risk (and its 95% CI) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). Abbreviations: CI: conf idence interval; RR: risk ratio; HR: hazard ratio.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate certainty: f urther research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate.
Low certainty: f urther research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low certainty: we are very uncertain about the estim ate.
B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is an important cause of childhood morbidity and death especially in HIV-positive children (Kochi 1991; Donald 2002) . Infection is caused by Mycobacterium tuberculosis and most commonly results in acute and chronic respiratory disease (Foster 2003). In 1994, the incidence of childhood TB increased in low-and middle-income countries (Nelson 2004 (Whalen 1995; Goletti 1996) . TB is a common cause of acute pneumonia in African HIV-positive children (Zar 2001; Jeena 2002) , and may lead to chronic lung disease, including bronchiectasis (Ikeogu 1997; Jeena 1998) . TB is a common cause of death in HIV-positive children (Ikeogu 1997; Chintu 2005) . Antimycobacterial drugs, such as rifampicin, have deleterious drug interactions with antiretroviral therapy (ART), complicating treatment. Rifampicin, an inducer of cytochrome P450 CYP3A, decreases the concentration of both the protease inhibitors and nonnucleoside reverse transcriptase inhibitors, leading to sub-therapeutic levels, and increasing the risk for inadequate viral suppression and consequent drug resistance (Ren 2008; Ren 2009). The large pill burden of two multiple drug regimens increases the risk of adverse events, such as liver toxicity and the likelihood of poorer adherence (Burman 2005). Conversely, HIV infection has an impact on TB disease. HIVpositive children have a higher risk of developing primary TB than HIV-negative children (Mukadi 1997; Hesseling 2009 ). The diagnosis of TB is more difficult in HIV-positive children, as other infections or HIV disease may mimic TB. Furthermore, tuberculin skin testing is less sensitive due to immunosuppression, and chest radiography is less specific (Berggren Palme 2002; Chintu 2005) . The outcome of HIV-positive versus HIV-negative children with TB co-infection is poorer, with six-fold increased death in HIV-positive children not on ART (Berggren Palme 2002; Hesseling 2005) . The cure rate of TB in HIV-positive children not on ART is significantly lower than in HIV-negative children (Mukadi 1997; Berggren Palme 2002) , with a higher rate of recur-rence (Schaaf 2005) . HIV-positive children may therefore require a longer course of TB treatment (Perriens 1995; Schaaf 1998) . HIV-positive children, stable on ART, are less likely to develop TB disease and have a better outcome than those not on ART (Walters 2008; Edmonds 2009; Martinson 2009 ). However, the initiation of ART in the setting of TB co-infection can lead to a paradoxical worsening of TB from the 'immune reconstitution syndrome' (Narita 1998; Puthanakit 2006; Zampoli 2007; Smith 2009 ). Moreover, the risk of TB in HIV-positive children on ART is still higher than that of HIV-negative children (Madhi 2011).
Description of the intervention
Isoniazid preventive treatment (IPT) is a secondary prevention strategy, whereby isoniazid prevents progression of latent TB to active TB in those at high-risk of developing active TB (Cohen 2006) . The WHO currently recommends that HIV/AIDS programmes include IPT as part of their package of care for HIVpositive people. Current guidelines recommend six months of IPT for HIV-positive children aged one year and above, without TB disease, even in the absence of a known TB contact; IPT for up to 3 years of use is recommended in HIV-positive adolescents or adults (WHO 2010; WHO 2011).
How the intervention might work
Preventing TB infection and disease in HIV-positive children is potentially an important public health intervention. Isoniazid has been used successfully as preventive treatment in HIV-negative children following TB exposure (Smieja 1999), and in HIV-infected adults with a positive tuberculin skin test (Akolo 2010), where treatment reduced TB disease by 62%.This benefit was found for all preventive drug regimens: isoniazid alone, isoniazid with rifampicin, rifampicin with pyrazinamide and isoniazid, rifampicin and pyrazinamide. No reduction in death was found. Isoniazid offers a further 40% reduction in active TB among HIVpositive adults on ART (Rangaka 2014). Studies showed that IPT reduces active TB at the community and population level (Grant 2005 ) . However, the strategy may be compromised by low adherence over the many months necessary to complete a single course of IPT, a problem worsened in HIV-TB co-infected individuals for whom IPT durations are prolonged. In contrast to adults, preventive treatment in children is aimed at preventing primary infection rather than reactivation of disease (WHO 2011). In settings of high TB prevalence, the rate of TB re-infection is high (Verver 2005) , and short-course prophylaxis is potentially inadequate. Longer-term prophylaxis or repeat courses may be necessary. Preventive treatment can lead to adverse events, mostly liver toxicity, although this is uncommon and rarely requires cessation of antimycobacterial medication in HIV-positive children (Gray 2009a; Donald 2000; Gray 2009a; Le Roux 2013) .The benefits of isoniazid outweigh the risk of liver damage for HIV-infected people (Getahun 2010).
Why it is important to do this review
In high-TB prevalence areas, TB preventive treatment may be effective in preventing infection and development of disease in HIV-positive children. The efficacy of preventive treatment may, however, be limited by adherence difficulties, adverse events, and cost implications. The true efficacy of TB preventive treatment in HIV-positive children must be clearly established and balanced against the occurrence of these events. We decided to undertake a Cochrane Review on the efficacy and safety of TB preventive treatment in HIV-positive children with prophylaxis started in all children diagnosed with HIV infection.
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) that evaluated the efficacy of TB preventive treatment in participants randomly allocated to preventive treatment for TB and placebo.
Types of participants
We included HIV-positive children, below 13 years, without TB disease currently (irrespective of prior history of TB treatment, infection or prophylaxis). We included children on antiretroviral therapy (ART). For studies that included eligible and non-eligible participants, we included only effect estimates of eligible participants.
Types of interventions
• Intervention group: any TB drug or drug combination.
• Comparison group: inactive placebo.
We did not impose any restrictions on study interventions, such as dose, duration of treatment, timing of outcome measurement, or co-interventions.
Types of outcome measures
Primary outcomes
• Active TB We defined definite TB by a microbiological or histological identification of Mycobacterium tuberculosis. We based the diagnosis of probable TB on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial treatment.
Secondary outcomes
• Death • Grade 3 or higher clinical adverse events • Peripheral neuropathy (defined as sensory alteration or paraesthesia causing inability to perform usual social and functional activities or disabling sensory alteration or paraesthesia causing inability to perform age appropriate basic self-care functions) (NIAID 2014)
• Other clinical adverse events
• Grade 3 or higher laboratory adverse events • Haematological abnormalities (defined as neutrophil count of 500/mm 3 to 749/mm 3 or < 500/mm 3 ; platelet count of 25,000 to 49,999/mm 3 or < 25,000/mm 3 ; haemoglobin of 6.5 g/dL to 7.5 g/dL or < 6.5 g/dL) (NIAID 2014)
• Liver enzyme abnormalities (raised alanine aminotransferase and aspartate aminotransferase of 5.1 to 10 or > 10, the upper limit of normal) (NIAID 2014)
• Other laboratory adverse events
We graded adverse events according to the standardized paediatric AIDS clinical trial grading system of severity of adverse events (NIAID 2014).
Search methods for identification of studies
Electronic searches
We searched:
• MEDLINE/PubMed (1946 to 17 February 2017) Appendix 1;
• Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (17 February 2017) Appendix 2; and
• Embase (1974 to 17 February 2017) Appendix 3.
We also searched for ongoing RCTs of chemoprophylaxis in HIVpositive children in:
• World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) ( www.who.int/ictrp; to 17 February 2017); and
• US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ( www.clinicaltrials.gov; to 17 February 2017).
Searching other resources
We handsearched reference lists of identified articles and review articles. We screened abstracts and proceedings of the International Union Against Tuberculosis and Lung Disease (IUATLD) World Congress, the American Thoracic Society International Congress, and the European Respiratory Society World Congress conferences. We contacted investigators of identified trials and other content experts to locate information on any further trials that may not have been included in the electronic databases or presented at conferences, to find out whether these were completed, ongoing, or published. We scrutinized non-Cochrane reviews for any additional relevant studies or unpublished data.
Data collection and analysis
Selection of studies MZ and TY scrutinized studies independently for eligibility. We retrieved the full text of relevant articles and independently examined them for eligibility. We included studies if they met the prespecified eligibility criteria. Authors assessing study eligibility were not blinded to the names of the trial investigators, their institutions, journals of publication or results of study. Reasons for excluding studies are summarized in Characteristics of excluded studies. We record the selection process in sufficient detail to complete a PRISMA flow diagram Liberati 2009.
Data extraction and management
MZ and a research assistant (OA) extracted the data. The following study characteristics and outcomes were independently extracted in duplicate, under the following subheadings:
• Methods (study design, study duration, methodological quality).
• Participants (inclusion and exclusion criteria, number of patients randomized, setting).
• Interventions (allocated treatment and dosage regimen, treatment duration)
• Outcomes (active TB, death, clinical and laboratory adverse events).
• Study results (number of participants with event of interest and the total number in that study arm for dichotomous outcomes; number lost to follow-up, and how incomplete data were addressed) Review authors who authored an included study did not participate in data extraction and assessment of risk of bias of included studies to maintain independence of the review. We summarized data in the Characteristics of included studies tables.
Assessment of risk of bias in included studies
We used Cochrane's 'Risk of bias' tool to assess the included studies (Deeks 2008; Higgins 2011). MZ and OA independently assessed the methodological quality of the included studies. We assessed the following domains.
• The adequacy of generation of allocation sequence and allocation concealment in preventing selection bias.
• The presence or absence of blinding of the participant and personnel to reduce performance bias.
• The method of outcome assessment: whether the same method of assessment was used in both groups and presence or absence of blinding of outcome assessor in the prevention of detection bias.
• Attrition bias by looking at the percentage of participants included in final analyses and the description of those not included. We also assessed whether or not an intention-to-treat analysis was performed.
• We compared protocols of included studies with published articles to assess for risk of selective reporting bias.
• Other bias.
We assigned the following judgements for risk of bias for each domain: low risk, high risk, and unclear risk of bias. We resolved disagreements on eligibility and methodological quality of trials by discussion and by obtaining further information from trial authors. We summarized data in a 'Risk of bias' table and graph, which shows our judgements on risk of bias in each domain, for each study separately, and as a percentage across all included studies.
Measures of treatment effect
For binary outcomes, we calculated risk ratios (RRs) and associated 95% confidence intervals (CIs). We assessed the effect of the intervention (isoniazid prophylaxis) compared to control (placebo) on the time to event (death and developing TB) with the hazard and incidence rate ratios (95% CI) presented in study reports.
Dealing with missing data
Two included trials used an intention-to-treat analysis to address missing data from participant dropout and the attrition rate was low in the third trial. We contacted the primary author of one included study for missing summary statistics, however, the author did not respond.
Assessment of heterogeneity
We used the Chi 2 test and I 2 statistic to assess statistical heterogeneity (Deeks 2008). We considered statistical heterogeneity to be substantial when the Chi 2 test, which assesses if the observed differences in results are due to chance alone, had a P value of < 0.10 and when the I 2 statistic, describing the percentage of variability in effect estimates due to heterogeneity, was > 50%.
Assessment of reporting biases
There were too few studies to enable investigation of publication bias using funnel plots.
Unit of analysis issues
All included trials followed a simple parallel group design, where children were individually randomized to either isoniazid prophylaxis or placebo group and a single measurement for each outcome (i.e. active TB or death) was collected and analyzed.
Data synthesis
We used a fixed-effect meta-analysis incorporating the Mantel-Haenszel method for dichotomous outcomes and the inverse-variance method for time-to-event outcomes to pool results across studies with no significant heterogeneity (Deeks 2008). Where meta-analysis was inappropriate, we reported individual study results separately. We used Review Manager 5 for analysis (Review Manager 2014) . We stratified the analysis by whether the children were receiving ART or not.
Assessment of overall certainty of evidence
We used GRADE methodology to assess the overall certainty of evidence (Guyatt 2008). In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of evidence: methodological limitations, unexplained heterogeneity or inconsistency of study results, indirectness of evidence, imprecision of results, and risk for publication bias. We rated the certainty across studies as high, moderate, low, or very low. We used GRADEpro software to create two 'Summary of findings' tables for the comparisons 'isoniazid prophylaxis compared to placebo for HIV-positive children not on ART' and 'isoniazid prophylaxis compared to placebo for HIV-positive children on ART' (GRADEpro GDT 2014). We included active TB and death outcomes in the 'Summary of findings' tables. MZ and OA independently assessed the certainty of the evidence. We resolved disagreements on certainty ratings by discussion and provided justification for decisions to down-or upgrade the ratings using footnotes in the 'Summary of findings' table and made comments to aid readers' understanding of the review, where necessary. We used plain language statements to report these findings in the review.
Subgroup analysis and investigation of heterogeneity
We considered a subgroup analysis based on background TB prevalence, but all studies were from high TB prevalence settings. We will consider subgroup analysis by background TB prevalence in subsequent review updates.
Sensitivity analysis
We could not perform sensitivity analysis due to limited number of trials included in the review.
R E S U L T S
Description of studies
Results of the search
In the updated search (17 February 2017) we identified an additional two RCTs with 714 participants. We found no ongoing studies in the updated search ( Figure 1) .
Included studies
Design
We included three randomized controlled trials (RCTs) with a total of 991 participants in the review (Characteristics of included studies). Two trials were conducted in South Africa (Gray 2014; Zar 2007), and one was a multicentre trial that was conducted in South Africa and Botswana; however, enrolment in Botswana began shortly before the study was terminated (Madhi 2011). 
Participants
Interventions
Included studies randomly assigned children to isoniazid prophylaxis or placebo group. The dose of isoniazid prophylaxis (10 mg/ kg with a variability of 8 mg/kg to 12 mg/kg) and frequency of treatment (either daily or three times weekly) were similar in Zar 2007 and Gray 2014 compared to Madhi 2011, where children received 10 mg/kg to 20 mg/kg of isoniazid daily. Children assigned to the control groups received placebo with identical appearance to isoniazid prophylaxis tablets, and administered in a similar way to isoniazid prophylaxis in the respective studies. In Zar 2007, ART was initiated in 9% of children at baseline and in 22% during the trial. In Madhi 2011, ART was initiated at baseline in approximately 20% of HIV-positive children and in 98.9% within the first year. All children in Gray 2014 were on ART. The analysis was stratified as such. In addition, only HIVpositive children in Zar 2007 and Madhi 2011 received 5 mg/kg of cotrimoxazole.
Primary outcome
Active TB was similarly defined across all three trials (see the 'Types of outcome measures' section).
Excluded studies
We excluded six studies on review of full articles, see Characteristics of excluded studies tables for details.
Risk of bias in included studies
We have presented the risk of bias for each included trial in the 'Risk of bias' table in the 'Characteristics of included studies' tables. The 'Risk of bias' summary presents the review authors' judgements on the risk of bias in each domain, for each trial separately (Figure 2 ), while the 'Risk of bias' graph presents the risk of bias in each domain as a percentage across all included trials ( Figure  3) . A summary of our findings on study methodological quality for each domain follows below. 
Blinding
In Zar 2007, participants, personnel, and investigators assessing the outcome, including an independent outcome assessor, were blinded to study treatment allocation. Participants, caregivers, investigators, and end point review committee were unaware of study group assignment in Madhi 2011. Participants and personnel were blinded in Gray 2014. The radiologist and the clinician (outcomes assessors) were blinded to the prophylactic regimen to which the child was allocated (Gray 2014). We assessed the three studies as having low risk of participant and personnel performance bias and detection bias (Zar 2007; Madhi 2011; Gray 2014) .
Incomplete outcome data
The three studies were at low risk of attrition bias, because the attrition rate was below 20% in one study (Zar 2007) , and all participants randomized were included in analysis in two trials (Madhi 2011; Gray 2014).
Selective reporting
We judged risk of reporting bias to be low in all three trials (Zar 2007; Madhi 2011; Gray 2014). All outcomes stated in the study protocols were reported in the published manuscripts.
Other potential sources of bias
The risk of other bias was unclear in one study; the data safety monitoring board recommended randomization into the placebo group to be stopped after 277 of the planned 432 participants were enrolled (Zar 2007). Two studies were at low risk of other potential sources of bias (Madhi 2011; Gray 2014). 
Effects of interventions
Active tuberculosis (TB)
One trial from South Africa assessed the effects of isoniazid prophylaxis in HIV-positive children not taking ART. This trial was stopped early when 263 of 432 (61%) planned participants had been recruited, due to a result that had reached standard levels of statistical significance. Isoniazid prophylaxis reduce the number of children developing active TB by 69% (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, (review authors own figures), low certainty evidence). The number of events in this trial was very low. Therefore, we judged the result to be of low certainty, when downgraded for serious indirectness and imprecision (Summary of findings for the main comparison).
Death
In children not taking ART, isoniazid prophylaxis reduces death by more than 50% (risk ratio (RR) 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, (review authors own figures), low certainty evidence; Summary of findings for the main comparison). We downgraded the trial for serious indirectness and imprecision.
Clinical adverse events (grade 3 or higher)
One trial (Zar 2007) reported no clinical adverse events in children not on ART (Table 1) .
Laboratory adverse events (grade 3 or higher)
One trial (182 participants) reported the number of children not on ART with laboratory adverse events (Zar 2007) (Table 1) . Five and six children had haematological abnormalities (RR 0.83, 95% CI 0.26 to 2.63) in the isoniazid prophylaxis and placebo groups, respectively. None of the children in the isoniazid prophylaxis group, but two in the placebo group had liver enzyme abnormalities.
HIV-positive children on antiretroviral therapy (ART)
Active TB
In HIV-positive children on ART, isoniazid prophylaxis conferred neither benefit nor harm on active TB (RR 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, very low certainty evidence; Analysis 1.1; Figure 4 ; Summary of findings 2). The trials and the metaanalysis were underpowered to detect clinically important effects and consequently the 95% CI is wide ( Table 2 ). The vast majority of data were from South Africa, limiting the broad generalization of the findings to other settings. 
Death
Isoniazid prophylaxis conferred neither benefit nor harm on death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, very low certainty evidence; Analysis 1.2; Figure 5 ; Summary of findings 2). The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on death (Table 2) . We downgraded the trials for indirectness and serious imprecision. 
Clinical adverse events (grade 3 or higher)
Two trials (714 participants) reported number of clinical adverse events (Table 1) . Three and two peripheral neuropathy abnormalities occurred in the isoniazid prophylaxis and placebo groups, respectively (Madhi 2011); 15 and 24 other clinical adverse events respectively, occurred in the isoniazid prophylaxis and placebo groups (Madhi 2011; Gray 2014).
Laboratory adverse events (grade 3 or higher)
Three trials (795 participants) reported number of laboratory adverse events (Table 1 ). There were 10 and 9 haematological abnormalities in the isoniazid prophylaxis and placebo groups (Madhi 2011); and 15 and 13 liver enzyme abnormalities in the isoniazid prophylaxis and placebo groups, respectively (Madhi 2011; Gray 2014).
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Isoniazid prophylaxis compared to placebo for HIV-positive children on antiretroviral therapy (ART) The basis f or the assumed risk is the m edian control group risk across studies. The corresponding risk (and its 95% CI) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). Abbreviations: CI: conf idence interval; RR: risk ratio.
GRADE Working Group grades of evidence
D I S C U S S I O N
Summary of main results
In HIV-positive children not taking antiretroviral therapy (ART), isoniazid prophylaxis may reduce active TB disease (low certainty evidence), and death (low certainty evidence). In HIV-positive children without known exposure to a TB source case, and on ART, isoniazid prophylaxis conferred neither benefit nor harm for active TB (very low certainty evidence) or death (very low certainty evidence). HIV treatment may modify the effect of TB preventive treatment. Clinical adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. Laboratory adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. In a secondary analysis of Zar 2007 data, Le Roux 2013 showed that 16 (5.4%) out of 297 children developed severe liver injury while receiving isoniazid, but that only 1.7% of these cases were related to isoniazid prophylaxis.
Overall completeness and applicability of evidence
Isoniazid preventive therapy is currently recommended for preventing TB infection in HIV-positive children. We included three trials (n = 991) in this review, which enrolled both young and older HIV-positive children, living in areas of high TB prevalence. Most of the data were from South Africa, limiting the generalizability of the review findings to other settings, given the variation in isoniazid resistance globally. The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on active TB and death in HIV-positive children taking ART. ART is known to protect against TB disease, and adequately powered randomized controlled trials (RCTs) are therefore required to assess the possibility of isoniazid prophylaxis efficacy added to ART. Further data on isoniazid prophylaxis efficacy at varying levels of immunosuppression (HIV disease) are required.
Quality of the evidence
We used the GRADE approach to rate the certainty of the evidence GRADEpro GDT 2014. In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of the evidence: methodological limitations, inconsistency in study results, indirectness, imprecision, and publication bias. We presented the evidence in two 'Summary of findings' tables for isoniazid prophylaxis efficacy; one for HIV-positive children not on ART (Summary of findings for the main comparison), and the other for HIV-positive children on ART (Summary of findings 2). The evidence on the effect of isoniazid prophylaxis for active TB and death in HIV-positive children not on ART was of low certainty. The effect of isoniazid prophylaxis for active TB and death in HIV-positive children on ART was inconclusive and the evidence was of very low certainty. We downgraded the trials for serious indirectness and imprecision because all were conducted in one setting and were underpowered with wide confidence intervals.
Potential biases in the review process
We conducted an extensive and comprehensive search of electronic databases, with no language restrictions, to identify published and unpublished trials. MZ and TY independently performed study selection. MZ and OA independently extracted the data and assessed the methodological quality of included studies. Review authors who authored an included study, were not involved in extraction of data and assessment of methodological quality of any included studies, to maintain independence of the review.
Agreements and disagreements with other studies or reviews
The results of this review were similar to those from a review of isoniazid prophylaxis in adults (Akolo 2010). Isoniazid prophylaxis had a greater protective effect on TB disease in HIV-positive children not on ART, reducing the chance of developing active childhood TB disease by 69%, similar to the 62% reduction in risk of active disease, found in the adult review (Akolo 2010). Evidence on impact of isoniazid prophylaxis on death in HIV-positive children not on ART, showed a 54% reduction in death (Zar 2007) . In contrast, isoniazid prophylaxis had no significant effect on TB disease and death in HIV-positive children on ART; these findings were consistent with the Akolo 2010 review in HIV-positive adults, reporting no effect on death, in a comparison of any drug for TB versus placebo. These findings may be consistent with the protective effect of ART, in reducing the risk of TB disease and death in HIV-positive children.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Isoniazid prophylaxis may reduce active tuberculosis (TB) disease and death in HIV-positive children not on antiretroviral therapy (ART). The WHO 2013 guidelines recommend ART for all HIV-positive children, which has to be started soon after diagnosis (WHO 2013). However, many children have delayed access to ART and coverage is not universal in most sub-Saharan settings, suggesting that any child awaiting ART in a high TB prevalence area, should have isoniazid prophylaxis until the child is virally suppressed and immune reconstituted. Baseline risk of HIV-positive children on ART, benefits and harms should be considered when making treatment decisions.
Implications for research
The risk of TB is substantially higher in HIV-positive children on ART compared to HIV-negative children from the same community. In Madhi 2011, children on ART had a higher rate of TB disease, 121 cases per 1000 child-years than HIV-negative children, 41 per 1000 child-years. Adequately powered trials assessing the impact of TB preventive therapy in HIV-positive children on ART are required. A target sample size of 848 HIV-positive children on ART will be required to have an 80% chance of detecting a 43% relative reduction, as significant at the 5% level, in the intervention group assuming a 14% baseline risk in active TB disease outcome. Trials that assess the long-term effects of TB prophylaxis are also needed to better assess the length of benefit in different settings. The three included trials investigated isoniazid prophylaxis versus placebo. There are no data on the efficacy of other TB preventive treatment regimens. Studies in adults included multiple-drug combination preventive treatment (Akolo 2010). How-ever adverse events leading to discontinuation of treatment were more common for multiple-drug therapy, as opposed to isoniazid treatment alone (Akolo 2010).
Although most cases of definite TB in the included studies were sensitive to isoniazid prophylaxis, long-term data on the impact of isoniazid prophylaxis on Mycobacterium tuberculosis sensitivity are needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gray 2014
Methods
Trial design: double-blind, randomized placebo-controlled trial Follow-up: full blood count, liver function tests, urea and electrolyte tests, percentage of CD4 cells and viral load were measured at baseline and 6-monthly. CXR was performed at baseline, and additional CXRs were taken if clinically indicated Adverse events: symptoms of adverse reactions to INH were recorded at each study visit Participants Number of participants: 167 Median (IQR) age at baseline: 35 months (15 to 65) Inclusion criteria: age > 8 weeks, on ART for greater than 2 months, weight > 2.5 kg, adherence to ART of > 90%, prior history of TB treatment or prophylaxis, informed consent, resident in the area, access to transport Exclusion criteria: chronic diarrhoea, currently using isoniazid prophylaxis, exposure to a TB contact, history of prior isoniazid hypersensitivity, severe anaemia (haemoglobin less than 7 gm/dL), neutropenia (absolute neutrophil count less than 400 cells/µL), thrombocytopenia (platelet count less than 50 000/µL), non-reversible renal failure Interventions 1. Isoniazid, 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either three times weekly or daily for a median duration of 34 months.
2. Placebo, had an identical appearance to isoniazid tablet, received either three times weekly or daily for a median duration of 34 months. All children were on ART and had adherence of at least 90% at baseline Outcomes 
Zar 2007
Methods
Trial design: double-blind, placebo-controlled trial. Follow-up: children underwent a tuberculin skin test and chest radiography if clinically indicated Adverse events: alanine transaminase were measured one and three months after randomization and thereafter six-monthly or more frequently if clinically indicated Participants Number of participants: 277 Median (IQR) age at baseline: 25 months (9 to 52) Inclusion criteria: age > 8 weeks, weight > 2.5 kg, access to transport, informed consent, children stable on ART for two to three months Exclusion criteria: chronic diarrhoea, current use of or need for isoniazid prophylaxis, previous hypersensitivity to isoniazid or sulphur containing drugs, haemoglobin < 70 g/ L, neutrophil count < 400 cell/uL, platelet count < 50,000 x10 9 /L, non-reversible renal failure.
Interventions 1. Isoniazid: 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either daily or three times a week on Monday, Wednesday, and Friday for a median duration of 5.7 months.
2. Placebo, identical in appearance to isoniazid tablets, either daily or three times a (1) Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.
D A T A A N D A N A L Y S E S
Comparison 1. Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART)
(2) Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo.
(3) ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo Analysis 1.2. Comparison 1 Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART), Outcome 2 Death.
Review: Isoniazid for preventing tuberculosis in HIV-infected children (1) Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.
(2) ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo
(3) Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo. 
A D D I T I O N A L T A B L E S
